INTEGRATED BIOPHARMA INC

OTC:INBP

Pharmaceutical Preparations·HILLSIDE, NJ

CEO

Kay Christina

CFO

Masi Dina

Summary Financials

Revenue

$47.0M

+28.3% YoY

FY 2018

Adj. EBITDA

$558,000

1.2% margin

FY 2025

Net Income

$112,000

0.2% margin

FY 2025

EPS (Diluted)

$0.00

FY 2025

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$1.7M

FY 2025

Total Debt

$7.1M

FY 2023

Net Debt

$5.4M

FY 2023

Enterprise Value

—

Debt / EBITDA

9.6x

FY 2018

EV / EBITDA

—

Employees

—

Revenue

$47.0M

+28.3% YoY

FY 2018

Adj. EBITDA

$558,000

1.2% margin

FY 2025

Net Income

$112,000

0.2% margin

FY 2025

EPS (Diluted)

$0.00

FY 2025

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$1.7M

FY 2025

Total Debt

$7.1M

FY 2023

Net Debt

$5.4M

FY 2023

Enterprise Value

—

Debt / EBITDA

9.6x

FY 2018

EV / EBITDA

—

Employees

—